6919 — Caliway Biopharmaceuticals Co Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapSucker Stock

Annual balance sheet for Caliway Biopharmaceuticals Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	595	1,111	3,712	9,669	4,860
Net Total Accounts Receivable
Net Total Receivables	—	3.12	7.89	5.18	6.49
Total Inventory
Total Other Current Assets
Total Current Assets	605	1,132	3,744	9,706	4,991
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	106	99.6	80.4	61.3	50.8
Long Term Investments
Other Long Term Assets
Total Assets	713	1,233	3,827	9,771	9,474
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	39.7	48.4	73.7	52.7	45.5
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Funded Status
Total Liabilities	68.2	68.8	85.6	73.7	63.7
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
Unrealized Gain / Loss
Other Equity
Total Equity	645	1,164	3,741	9,697	9,410
Total Liabilities & Shareholders' Equity	713	1,233	3,827	9,771	9,474
Total Common Shares Outstanding